Future perspectives in melanoma research. Meeting report from the " Melanoma Bridge. Napoli, December 2nd-4th 2012"

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Ascierto, Paolo A ^a   Grimaldi, Antonio M ^a   Acquavella, Nicolas ^b   Borgognoni, Lorenzo ^c   Calabrò, Luana ^d   Cascinelli, Natale ^e   Cesano, Alessandra ^f   Del Vecchio, Michele ^g   Eggermont, Alexander M ^h   Faries, Mark ⁱ   Ferrone, Soldano ^j   Fox, Bernard A ^k,l   Gajewski, Thomas F ^m   Galon, Jérôme ^n,o   Gnjatic, Sacha ^p   Gogas, Helen ^q   Kashani Sabet, Mohammed ^r   Kaufman, Howard L ^s   Larkin, James ^t   Lo, Roger S ^u   Mantovani, Alberto ^v   Margolin, Kim ^w   Melief, Cornelis ^x   McArthur, Grant ^y   Palmieri, Giuseppe ^z   Puzanov, Igor ^aa   Ribas, Antoni ^u   Seliger, Barbara ^ab   Sosman, Jeff ^ac   Suenaert, Peter ^ad   Tarhini, Ahmad A ^ae   Trinchieri, Giorgio ^af   Vidal Vanaclocha, Fernando ^ag   Wang, Ena ^ah   Ciliberto, Gennaro ^a   Mozzillo, Nicola ^a   Marincola, Francesco M ^ai   Thurin, Magdalena ^b   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF SIENA   (Italy)

^e WHO Melanoma Programme   (Italy)

^f Nodality Inc   (United States)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ JOHN WAYNE CANCER INSTITUTE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ CENTRE DE RECHERCHE DES CORDELIERS   (France)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^r CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^s RUSH UNIVERSITY   (United States)

^t INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^w UNIVERSITY OF WASHINGTON   (United States)

^x LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^y PETER MACCALLUM CANCER CENTRE   (Australia)

^z CNR   (Italy)

^aa VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ab MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^ac VANDERBILT INGRAM CANCER CENTER   (United States)

^ad GSK   (Belgium)

^ae UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^af NATIONAL CANCER INSTITUTE   (United States)

^ag UNIVERSIDAD SAN PABLO CEU   (Spain)

^ah NATIONAL INSTITUTES OF HEALTH   (United States)

^ai SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; CANCER VACCINE; CELECOXIB; CISPLATIN; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 3 VACCINE; MELPHALAN; ONAMELATUCEL L; PACLITAXEL; PALBOCICLIB; PEGINTERFERON ALPHA2B; PLACEBO; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VEMURAFENIB; VINBLASTINE;

ADOPTIVE IMMUNOTHERAPY; AREA UNDER THE CURVE; BONE MARROW TOXICITY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONFERENCE PAPER; CUTANEOUS MELANOMA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; ELECTROCHEMOTHERAPY; FATIGUE; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; LIVER CANCER; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTATIC MELANOMA; MYALGIA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHOTOSENSITIVITY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDICAL ONCOLOGY; MELANOMA; MUTATION; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878374050     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-137     Document Type: Conference Paper

References (116)

1. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-727.
2. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534. 10.1200/JCO.2007.12.7837, 18235113.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819. 10.1056/NEJMoa1002011, 20818844.
4. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901. 10.1016/S0140-6736(12)60398-5, 22608338.
5. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693. 10.1016/S0952-7915(97)80050-7, 9368778.
6. Gérard C, Baudson N, Ory T, Piccininno R, Brichard V. Comprehensive preclinical model evaluating a protein-based MAGE-A3 specific cancer immunotherapy to fight against MAGE-A3 expressing tumors [abstract]. Eur J Canc 2006, 4:39.
7. Kruit WH, Suciu S, Dreno B, Chiarion-Sileni V, Mortier L, Robert C, Maio M, Brichard V, Spatz A, Eggermont A, Keilholz U, Lehmann F. Immunization with the recombinant MAGE-A3 protein combined with Adjuvant Systems AS02B or AS15 in patients with metastatic melanoma: final results of a Phase II study of the EORTC Melanoma Group [abstract]. Perspectives in Melanoma 2009, 0-0001.
8. Louahed J, Lehmann F, Ulloa-Montoya F, Gruselle O, Dizier B, Vansteenkiste J, Kruit W, Brichard V. Identification of a gene expression signature predictive of clinical activity following MAGE-A3 ASCI treatment [abstract]. Mol Cancer Ther 2009, 8(12 supplements):1. 2775557, 19139107.
9. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011, 108:16723-16728. 10.1073/pnas.1110814108, 3189057, 21933959.
10. O'Donnell-Tormey J, McDermott EA. The cancer vaccine collaborative: a new model of coordinated discovery. Cancer Immun 2012, 12:10. 3380350, 22896755.
11. Wheatley K, Ives N, Eggermont A, Kirkwood J, Cascinelli N, Markovic SN, Hancock B, Lee S, Suciu S, on behalf of International Malignant Melanoma Collaborative Group Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials [abstract]. Proc Am Soc Clin Oncol 2007, 25:478S. abstr 8526, on behalf of International Malignant Melanoma Collaborative Group.
12. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501. 10.1093/jnci/djq009, 20179267.
13. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171. 10.1200/JCO.2005.05.2498, 16809739.
14. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007, 13:1523-1531. 10.1158/1078-0432.CCR-06-1387, 17332298.
15. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007, 13:2422-2428. 10.1158/1078-0432.CCR-06-1805, 17438101.
16. Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosserhoff AK. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 2010, 19:e251-e257.
17. Wang E, Zhao Y, Monaco A, Uccellini L, Kirkwood JM, Spyropoulou-Vlachou M, Panelli MC, Marincola FM, Gogas H. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One 2012, 7:e40805. 10.1371/journal.pone.0040805, 3404079, 22911710.
18. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010, 116:4326-4333. 10.1002/cncr.25211, 2970916, 20549830.
19. Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med 2010, 8:108. 10.1186/1479-5876-8-108, 2988721, 21044351.
20. Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012, 10:146. 10.1186/1479-5876-10-146, 3527361, 22788688.
21. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud T, Gjertsen BT, Nolan GP. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228. 10.1016/j.cell.2004.06.028, 15260991.
22. Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta E. Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry B Clin Cytom 2012, 82:158-172. 3632455, 22334473.
23. Covey TM, Cesano A. Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications. Best Pract Res Clin Haematol 2010, 23:319-331. 10.1016/j.beha.2010.07.002, 21112033.
24. Covey TM, Cesano A, Parkinson DR. Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease. Autoimmunity 2010, 43:550-559. 10.3109/08916931003674774, 20482423.
25. Longo DM, Louie B, Putta S, Evensen E, Ptacek J, Cordeiro J, Wang E, Pos Z, Hawtin RE, Marincola FM, Cesano A. Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol 2012, 188:1717-1725. 10.4049/jimmunol.1102514, 3517183, 22246624.
26. Hotson D, Conroy A, Evensen E, Gentilcore G, Simeone E, Esposito A, Curvietto M, Cesano A, Hawtin R, Ascierto PA. CTLA-4 defines distinct T cell signaling populations in healthy donors and metastatic melanoma patients [abstract]. J Immunother 2012, 35(suppl. 9):760.
27. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR, Sagebiel RW. A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 2009, 15:6987-6992. 10.1158/1078-0432.CCR-09-1777, 2784204, 19887476.
28. De Semir D, Nosrati M, Bezrookove V, Dar AA, Federman S, Bienvenu G, Venna S, Rangel J, Climent J, Meyer Tamgüney TM, Thummala S, Tong S, Leong SP, Haqq C, Billings P, Miller JR, Sagebiel RW, Debs R, Kashani-Sabet M. Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. Proc Natl Acad Sci USA 2012, 109:7067-7072. 10.1073/pnas.1119949109, 3344978, 22511720.
29. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
30. Eggermont AM, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt CJA, Gore ME, MacKie R, Dummer R, Schadendorf D, Patel P, Spatz A, Keilholz U. EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up [abstract]. J Clin Oncol 2011, 29(abstr 8506b).
31. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718. 10.1056/NEJMoa053007, 16481638.
32. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62. 10.1186/1479-5876-6-62, 2605741, 18954464.
33. Kumar KG, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignantmelanoma cells. Cancer Biol Ther 2007, 6:1437-1441. 10.4161/cbt.6.9.4569, 2254442, 17873516.
34. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328. 10.1200/JCO.2011.37.5394, 3422533, 22184371.
35. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012, 72:5209-5218. 10.1158/0008-5472.CAN-12-1187, 22915761.
36. Lawson DH, Lee SJ, Tahrini AA, Margolin KK, Ernstoff MS, Kirkwood JM. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completed resected stage III-IV melanoma. J Clin Oncol 2010, 28(suppl):8507. abstract.
37. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Ribas A, Kirkwood JM, Sondak VK. Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG [abstract]. J Clin Oncol 2012, 30:8504. abstr.
38. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of " self" -reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998, 188:277-286. 10.1084/jem.188.2.277, 2212458, 9670040.
39. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, et al. A landscape of driver mutations in melanoma. Cell 2012, 150(2):251-263. 10.1016/j.cell.2012.06.024, 22817889.
40. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene 2010, 29:5545-5555. 10.1038/onc.2010.323, 3169242, 20697348.
41. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf (V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009, 41:544-552. 10.1038/ng.356, 2705918, 19282848.
42. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011, 17:4550-4557. 10.1158/1078-0432.CCR-11-0116, 3131487, 21498393.
43. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA. Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70(13):5213-5219. 10.1158/0008-5472.CAN-10-0118, 20551059.
44. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Oncogenic BRAF (V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 2008, 21:534-544. 10.1111/j.1755-148X.2008.00491.x, 18715233.
45. Boisvert-Adamo K, Aplin AE. Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 2008, 27:3301-3312. 10.1038/sj.onc.1211003, 18246127.
46. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203:1651-1656. 10.1084/jem.20051848, 2118331, 16801397.
47. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England J Med 2011, 364:2507-2516. BRIM-3 Study Group.
48. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, Nolop KB, Saltz L. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors [abstract]. J Clin Oncol 2010, 28(abstract 3534).
49. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-104. 10.1038/nature10868, 22281684.
50. Kim K, Cabanillas M, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring V600EBRAF Mutation. Thyroid 2013, [Epub ahead of print] PubMed PMID: 23489023.
51. A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers (NCT01524978). http://www.clinicaltrials.gov.
52. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70:5518-5527. 10.1158/0008-5472.CAN-10-0646, 20551065.
53. Sullivan RJ, Lawrence DP, Flaherty KT, McDermott DF, Aldridge J, Cho DC, Simonson R, Seery VJ, Hodi FS, Atkins MB, Mier JW, Panka DJ. Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay [abstract]. J Clin Oncol 2012, 30(abstr 8516).
54. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365. 10.1016/S0140-6736(12)60868-X, 22735384.
55. Gonzalez R, Ribas A, Daud A, Pavlick A, Gajewski TF, Puzanov I, Teng MSL, Chan I, Choong NW, McArthur G. Phase Ib study of vemurafenib in combination with the MEK inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM7) [abstract]. Ann Oncol 2012, 23:ixe20.
56. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC, Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002, 62:3395-3401.
57. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. J Clin Oncol 2013, Epub ahead of print.
58. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977. 10.1038/nature09626, 3143360, 21107323.
59. Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013, 3:350-362. 10.1158/2159-8290.CD-12-0470, 23288408.
60. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013, 3:338-349. 10.1158/2159-8290.CD-12-0313, 23171796.
61. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002, 2:938-950. 10.1038/nrc948, 12459732.
62. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005, 11:2416-2426. 10.1158/1078-0432.CCR-04-1380, 15788693.
63. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27:5763-5771. 10.1200/JCO.2009.24.3675, 19884534.
64. Trinchieri G. Gut commensal bacteria determine cancer response to treatment by modulating systemic inflammation [abstract]. Ann Oncol 2013, 24:i12.
65. Trinchieri G. Cancer and Inflammation: An old intuition with rapidly evolving new concepts. Annual Rev Immunology 2012, 30:677-706.
66. Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M, Stephens R, Dai RM, Lyakh L, Schenten D, Yuspa HS, Trinchieri G. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 2012, 209:1689-1702. 10.1084/jem.20101355, 3428947, 22908325.
67. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
68. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795. 10.1172/JCI59643, 3287223, 22378047.
69. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783. 10.1016/S0140-6736(08)60241-X, 18275997.
70. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance and open questions. Semin Immunopathology 2013, in press.
71. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010, 28:157-183. 10.1146/annurev-immunol-030409-101305, 19968561.
72. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616. 10.1126/science.1198443, 3406187, 21436454.
73. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the anti-tumor activity of Trabectedin. Cancer Cell 2013, 23:249-262. 10.1016/j.ccr.2013.01.008, 23410977.
74. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
75. Spatz A, Cook MG, Elder DE, Piepkorn M, Ruiter DJ, Barnhill RL. Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer 2003, 39:1861-1865. 10.1016/S0959-8049(03)00325-3, 12932663.
76. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006, 98:472-482. 10.1093/jnci/djj103, 16595783, Melanoma Group of the European Organization for Research and Treatment of Cancer.
77. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A, European Organization for Research and Treatment of Cancer Melanoma Group Long-term protective effect of mature DC-LAMP + dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res 2007, 13:3825-3830. 10.1158/1078-0432.CCR-07-0358, 17606713, European Organization for Research and Treatment of Cancer Melanoma Group.
78. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D, EORTC Melanoma Group Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366:1189-1196. 10.1016/S0140-6736(05)67482-X, 16198768, EORTC Melanoma Group.
79. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U, EORTC Melanoma Group Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126. 10.1016/S0140-6736(08)61033-8, 18620949, EORTC Melanoma Group.
80. Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Salès F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225. 10.1016/j.ejca.2011.09.028, 22056637.
81. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012, 30(31):3810-3818. 10.1200/JCO.2011.41.3799, 23008300.
82. McMasters KM, Edwards MJ, Ross MI, Reintgen DS, Martin RC, Urist MM, Noyes RD, Sussman JJ, Stromberg AJ, Scoggins CR. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg 2010, 252:460-465.
83. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892. 10.1056/NEJMoa1113205, 22397650.
84. Seghers AC, Wilgenhof S, Lebbé C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012, 22:466-472. 10.1097/CMR.0b013e3283541541, 22584957.
85. Koay E, Sulman EP. Management of brain metastasis: past lessons, modern management, and future considerations. Curr Oncol Rep 2012, 14:70-78. 10.1007/s11912-011-0205-9, 22071681.
86. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011, 365:2439-2441. 10.1056/NEJMc1111672, 22188003.
87. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005, 26:485-495. 10.1016/j.it.2005.07.004, 16039904.
88. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 2009, 15:7538-7546. 10.1158/1078-0432.CCR-09-1985, 2805170, 19996208.
89. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-1324. 10.1158/1078-0432.CCR-05-1634, 16489089.
90. Hersh E, Del Vecchio M, Brown M, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Haydon A, Robert C, Clawson A, Elias I, Renschler M, Hauschild A. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) versus dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM) [abstract]. Pigment Cell Melanoma Res 2012, 25:863.
91. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human memory T cell subset with stem cell-like properties. Nat Med 2011, 17:1290-1297. 10.1038/nm.2446, 3192229, 21926977.
92. Uccellini L, De Giorgi V, Zhao Y, Tumaini B, Erdenebileg N, Dudley ME, Tomei S, Bedognetti D, Ascierto ML, Liu Q, Simon R, Kottyan L, Kaufman KM, Harley JB, Wang E, Rosenberg SA, Marincola FM. IRF5 gene polymorphisms in melanoma. J Transl Med 2012, 10:170. 10.1186/1479-5876-10-170, 3492128, 22909381.
93. Wendler T, Herrmann K, Schnelzer A, Lasser T, Traub J, Kutter O, Ehlerding A, Scheidhauer K, Schuster T, Kiechle M, Schwaiger M, Ziegler N, Buck AK. First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging 2010, 37:1452-1461. 10.1007/s00259-010-1430-4, 20354851.
94. Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P, Salvadori A, Pimpinelli N, Reali UM, Borgognoni L. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 2007, 125:184-193. 10.1016/j.clim.2007.07.018, 17827069.
95. Gerlini G, Di Gennaro P, Mariotti G, Urso C, Chiarugi A, Caporale R, Pimpinelli N, Borgognoni L. Human Langerhans cells are immature in melanoma sentinel lymph nodes. Blood 2012, 119:4807-4808. 10.1182/blood-2011-12-401067, 22596171.
96. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L. Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 2013, 30:37-45. 10.1007/s10585-012-9505-1, 22735940.
97. Gerlini G, Di Gennaro P, Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 2012, 1:1655-1657. 10.4161/onci.21991, 3525636, 23264927.
98. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneouslyplaced catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005, 23:3465-3474. 10.1200/JCO.2005.00.927, 2374756, 15908655.
99. Pingpank JF, Hughes MS, Faries MB, Zager JS, Alexander HR, Royal R, Whitman ED, Nutting CW, Siskin GP, Agarwala SS. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma [abstract]. J Clin Oncol 2010, 28:18s. abstr. LBA8512.
100. Seliger B. Novel insights into molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012, 61:249-254. 10.1007/s00262-011-1153-9, 22120755.
101. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?. Cell Mol Life Sci 2011, 68:417-431. 10.1007/s00018-010-0583-4, 3426238, 21063893.
102. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004, 96:326-331. 10.1093/jnci/djh028, 14970281.
103. Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immuneresponses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res 2011, 17:6467-6481. 10.1158/1078-0432.CCR-11-0812, 3298078, 21810919.
104. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, der Meer DM B-V, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847. 10.1056/NEJMoa0810097, 19890126.
105. Welters MJ, Kenter GG, DeVosvanSteenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010, 107:11895-11899. 10.1073/pnas.1006500107, 2900675, 20547850.
106. Calabrò L, Danielli R, Sigalotti L, Maio M. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010, 37:460-467. 10.1053/j.seminoncol.2010.09.006, 21074061.
107. Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J, Dinarello CA. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006, 25:417-434. 10.1007/s10555-006-9013-3, 17001512.
108. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, Carrascal T, Walsh P, Reznikov LL, Kim SH, Novick D, Rubinstein M, Dinarello CA. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci 2000, 97:734-739. 10.1073/pnas.97.2.734, 15399, 10639148.
109. Crende O, Sabatino M, Valcárcel M, Carrascal T, Riestra P, López-Guerrero JA, Nagore E, Mandruzzato S, Wang E, Marincola FM, Vidal-Vanaclocha F. Metastatic lesions with interleukin-18 dependent and independent genes in advanced stage melanoma patients. Am J Pathol 2013, in press.
110. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
111. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12:298-306. 10.1038/nrc3245, 22419253.
112. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pagès F, Trajanoski Z, Galon J. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440. 10.1053/j.gastro.2009.10.057, 19909745.
113. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, Zatloukal K, Trajanoski Z, Berger A, Fridman WH, Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951. 10.1200/JCO.2008.19.6147, 19858404.
114. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29:610-618. 10.1200/JCO.2010.30.5425, 21245428.
115. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1. 10.1186/1479-5876-10-1, 3269368, 22214470.
116. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205. 10.1186/1479-5876-10-205, 3554496, 23034130.